No synaptic loss for Prana
Wednesday, 11 March, 2009
Melbourne biotech Prana Technology’s lead compound not only reduces the amount of beta amyloid in mice models of Alzheimer’s, but it actually prevents the loss of synapses, the company says.
PBT2, a metal-protein-attenuating compound that mediates the distribution of metal ions in neurons and is aimed at restoring neuronal function, is in Phase IIa trials in early Alzheimer’s.
The compound is based on the metals hypothesis of Alzheimer's, in which copper ions released from neurons abnormally combine with beta amyloid to generate oxygen free radicals, which then damage neural tissue.
By redistributing metal ions back into the neurons themselves, the amyloid plaques then fall apart and neuronal function is restored.
Prana will present new data on synapse loss prevention at an international conference this weekend.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
